「ca」の検索結果
163件：46～50件目を表示
-
CEO Message | About Senju | SENJU Pharmaceutical
ent medicines and services focusing on the ophthalmology field through our unique ideas and R&D capabilities.Throughout our history, we have cultivated a sense of values that we call “SENJU SENSE”...
http://www.senju.co.jp/english/about/message.html -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
he European Societies of Toxicology 開催日：2025年9月14日～2025年9月17日 開催地：Athens, GREECE Summary of nonclinical toxicity evaluation of SJP-0132, a TRPV1 antagonist Satoko Doi1, Satomi Kikuchi2, Yoshihisa Naka...
http://www.senju.co.jp/english/rd/society/ -
お知らせ | 千寿製薬株式会社
hthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） September 4, 2025 Senju has developed and obtain...
http://www.senju.co.jp/english/news/ -
Quality Policies | About Senju | SENJU Pharmaceutical
ways pay close attention to the quality of our products to provide customers with better pharmaceuticals and comply with laws and standards with high ethical standards on product quality, and exercise...
http://www.senju.co.jp/english/about/quality.html -
Company Profile | About Senju | SENJU Pharmaceutical
Corporate Name Senju Pharmaceutical Co.,Ltd. Headquarter 3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048,Japan TEL：+81-6-6201-2512 FAX：+81-6-6226-0406 Date of Incorporation April 9, 1947 Capital 1,415,50...
http://www.senju.co.jp/english/about/outline.html